NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Hao-Wen SimLuke WachsmuthElizabeth H BarnesSonia YipEng-Siew KohMerryn HallRoss JennensDavid M AshleyRoel G VerhaakAmy B HeimbergerMark A RosenthalElizabeth J HoveyBenjamin M EllingsonAnnette TognelaHui Kong GanHelen WheelerMichael BackKerrie L McDonaldAnne LongKatharine CuffStephen BegbieCraig GedyeAnna MislangHien LeMargaret O JohnsonBenjamin Y KongJohn R SimesZarnie LwinMustafa KhasrawPublished in: Neuro-oncology advances (2023)
Due to insufficient evidence of benefit with nivolumab, the decision was made not to transition to a phase III trial. No new safety signals were identified with nivolumab. This complements the existing series of immunotherapy trials. Research is needed to identify biomarkers and new strategies including combinations.